Dong Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dong Guo has a total of 418 co-authors. Here are the top co-authors by number of shared publications:
Kequan Fu
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China; School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China
14 shared publications- Laura H. Heitman
Leiden University
14 shared publications Wenchao Zhao
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China
12 shared publications- Adriaan P. Ijzerman
Leiden University Leiden The Netherlands
11 shared publications Adriaan P. Ijzerman
Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR) Leiden University Leiden The Netherlands
9 shared publicationsHaoran Zhang
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China
9 shared publications
Latest Publications
- 9 July 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110212
Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects
- 9 July 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110212
Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects
- Open Access
- 25 June 2026
- Published by Wiley in Aging Cell
- Vol. 25 (7) , e70609
Podocyte mPGES ‐2 Determines Renal Aging and Contributes to Senile Osteoporosis
Renal aging shortens healthspan and propagates organ dysfunction beyond the kidney, yet its molecular drivers remain incompletely defined. Here we identify microsomal prostaglandin E synthase‐2 (mPGES‐2) as a critical regulator of renal aging and its skeletal consequence. Genetic ablation of Ptges2 improved health indices in aged mice, prolonged median survival, and markedly alleviated glomerulosclerosis, podocyte injury, and renal senescence. Single‐cell transcriptomic analysis, together with podocyte‐ and tubule‐specific knockout models, showed that podocyte mPGES‐2, rather than tubular mPGES‐2, is the dominant intrarenal driver of aging‐related kidney injury. Mechanistically, mPGES‐2 promoted podocyte senescence through a PGE 2 /EP1 signaling axis. Podocyte‐specific Ptges2 deletion also mitigated age‐related osteoporosis and restored renal calcitriol and α‐klotho, supporting a kidney‐bone mechanism secondary to impaired renal endocrine function. Consistent with the genetic models, pharmacological inhibition of mPGES‐2 with SZ0232 attenuated renal aging and improved bone microarchitecture in aged mice. Both genetic deficiency and pharmacological inhibition of mPGES‐2 were well tolerated, with no overt adverse effects on major organs. These findings identify podocyte mPGES‐2 as a druggable determinant of renal aging and a potential therapeutic target for aging‐associated osteoporosis.
- 25 June 2026
- Published by Wiley in Aging Cell
- Vol. 25 (7) , e70609
Open AccessPodocyte mPGES ‐2 Determines Renal Aging and Contributes to Senile Osteoporosis
Renal aging shortens healthspan and propagates organ dysfunction beyond the kidney, yet its molecular drivers remain incompletely defined. Here we identify microsomal prostaglandin E synthase‐2 (mPGES‐2) as a critical regulator of renal aging and its skeletal consequence. Genetic ablation of Ptges2 improved health indices in aged mice, prolonged median survival, and markedly alleviated glomerulosclerosis, podocyte injury, and renal senescence. Single‐cell transcriptomic analysis, together with podocyte‐ and tubule‐specific knockout models, showed that podocyte mPGES‐2, rather than tubular mPGES‐2, is the dominant intrarenal driver of aging‐related kidney injury. Mechanistically, mPGES‐2 promoted podocyte senescence through a PGE 2 /EP1 signaling axis. Podocyte‐specific Ptges2 deletion also mitigated age‐related osteoporosis and restored renal calcitriol and α‐klotho, supporting a kidney‐bone mechanism secondary to impaired renal endocrine function. Consistent with the genetic models, pharmacological inhibition of mPGES‐2 with SZ0232 attenuated renal aging and improved bone microarchitecture in aged mice. Both genetic deficiency and pharmacological inhibition of mPGES‐2 were well tolerated, with no overt adverse effects on major organs. These findings identify podocyte mPGES‐2 as a druggable determinant of renal aging and a potential therapeutic target for aging‐associated osteoporosis.
- 7 April 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (15) , 4795-4800
Photochemical Alkylation of Heterocycles Enabled by Oxalic Dianion as Traceless Electron Donor
Herein, a catalyst- and metal-free strategy for the alkylation of various heterocycles was developed from readily available alkyl amines or carboxylic acids. Oxalic acid was the only inexpensive and commercially available reagent to realize the transformation under blue light irradiation at ambient temperature. The EDA complex formed between the Katritzky salt and oxalic dianion was the key to initiate the single electron transfer and generate the reactive alkyl radical to accomplish the alkylation with protonated nitrogen-containing heterocycles.
- 7 April 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (15) , 4795-4800
Photochemical Alkylation of Heterocycles Enabled by Oxalic Dianion as Traceless Electron Donor
Herein, a catalyst- and metal-free strategy for the alkylation of various heterocycles was developed from readily available alkyl amines or carboxylic acids. Oxalic acid was the only inexpensive and commercially available reagent to realize the transformation under blue light irradiation at ambient temperature. The EDA complex formed between the Katritzky salt and oxalic dianion was the key to initiate the single electron transfer and generate the reactive alkyl radical to accomplish the alkylation with protonated nitrogen-containing heterocycles.
- Open Access
- 23 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor
- 23 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor
- Open Access
- 3 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 103001
Biomimetic nanoplatform with multienzyme cascade activity boosting ROS generation and immune activation feedback for tumor therapy
- 3 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 103001
Open AccessBiomimetic nanoplatform with multienzyme cascade activity boosting ROS generation and immune activation feedback for tumor therapy
- 1 January 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (1) , 174-196
Discovery of a potent STAT3 inhibitor WR-S-647 for the treatment of ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 12.5 million individuals globally and is one of the most common causes of end-stage renal disease. It is typically associated with a gradual increase in the volume of numerous cysts in both kidneys. Recent studies have highlighted the critical role of signal transducer and activator of transcription 3 (STAT3) in ADPKD pathogenesis, as it is highly expressed and persistently activated in ADPKD kidneys. Through screening of our in-house compound library, we identified compound WR-S-647 (4e) as a potent and specific inhibitor of STAT3 with a binding affinity of 34 nM to STAT3. WR-S-647 suppressed the phosphorylation activation and nuclear localization of STAT3. In vitro, WR-S-647 remarkably suppressed cyst formation and expansion in a Madin-Darby canine kidney (MDCK) cyst model. Meanwhile, it effectively diminished cyst growth in an ex vivo embryonal renal cyst model and an in vivo Pkd1 knockout ADPKD mouse model. Our study identifies WR-S-647 as a potent STAT3-mediated inhibitor and provides preclinical proof-of-concept for its efficacy in reducing cyst growth in ADPKD models.
- 1 January 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (1) , 174-196
Discovery of a potent STAT3 inhibitor WR-S-647 for the treatment of ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 12.5 million individuals globally and is one of the most common causes of end-stage renal disease. It is typically associated with a gradual increase in the volume of numerous cysts in both kidneys. Recent studies have highlighted the critical role of signal transducer and activator of transcription 3 (STAT3) in ADPKD pathogenesis, as it is highly expressed and persistently activated in ADPKD kidneys. Through screening of our in-house compound library, we identified compound WR-S-647 (4e) as a potent and specific inhibitor of STAT3 with a binding affinity of 34 nM to STAT3. WR-S-647 suppressed the phosphorylation activation and nuclear localization of STAT3. In vitro, WR-S-647 remarkably suppressed cyst formation and expansion in a Madin-Darby canine kidney (MDCK) cyst model. Meanwhile, it effectively diminished cyst growth in an ex vivo embryonal renal cyst model and an in vivo Pkd1 knockout ADPKD mouse model. Our study identifies WR-S-647 as a potent STAT3-mediated inhibitor and provides preclinical proof-of-concept for its efficacy in reducing cyst growth in ADPKD models.
- 29 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 25438-25455
Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD). Most reported V2R antagonists share a benzoazacyclic scaffold with limited structural diversity. In this study, structural analysis of V2R bound to the FDA-approved V2R antagonist tolvaptan and a previously reported derivative (compound 18) revealed that the interaction with a hydrophobic subpocket formed by residues V2065.39, I2095.42, and F2876.51 plays a critical role in antagonistic activity. Guided by this structural insight, we designed a series of non-benzoazacyclic analogs. Compound 29 (XYDC2050) exhibited high V2R binding affinity (Ki = 2.8 ± 0.1 nM) and potent cAMP inhibition (IC50 = 12.0 ± 2.0 nM). Notably, XYDC2050 displayed 162-fold selectivity over V1AR, surpassing that of tolvaptan (123-fold). In vitro and in vivo studies demonstrated that XYDC2050 effectively suppressed renal cyst formation and slowed disease progression. These results support XYDC2050 as a potential lead compound for ADPKD therapy.
- 29 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 25438-25455
Discovery of Non-benzoazacyclic V 2 R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Vasopressin V2 receptor (V2R) is a validated therapeutic target for autosomal dominant polycystic kidney disease (ADPKD). Most reported V2R antagonists share a benzoazacyclic scaffold with limited structural diversity. In this study, structural analysis of V2R bound to the FDA-approved V2R antagonist tolvaptan and a previously reported derivative (compound 18) revealed that the interaction with a hydrophobic subpocket formed by residues V2065.39, I2095.42, and F2876.51 plays a critical role in antagonistic activity. Guided by this structural insight, we designed a series of non-benzoazacyclic analogs. Compound 29 (XYDC2050) exhibited high V2R binding affinity (Ki = 2.8 ± 0.1 nM) and potent cAMP inhibition (IC50 = 12.0 ± 2.0 nM). Notably, XYDC2050 displayed 162-fold selectivity over V1AR, surpassing that of tolvaptan (123-fold). In vitro and in vivo studies demonstrated that XYDC2050 effectively suppressed renal cyst formation and slowed disease progression. These results support XYDC2050 as a potential lead compound for ADPKD therapy.
- Open Access
- 4 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Structural insights into antagonist recognition by the vasopressin V2 receptor
The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.
- 4 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessStructural insights into antagonist recognition by the vasopressin V2 receptor
The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.
- 15 October 2025
- Published by Springer Nature in Nature Computational Science
- Vol. 5 (11) , 1017-1028
ECloudGen: leveraging electron clouds as a latent variable to scale up structure-based molecular design
Structure-based molecule generation represents a notable advancement in artificial intelligence-driven drug design. However, progress in this field is constrained by the scarcity of structural data on protein–ligand complexes. Here we propose a latent variable approach that bridges the gap between ligand-only data and protein–ligand complexes, enabling target-aware generative models to explore a broader chemical space, thereby enhancing the quality of molecular generation. Inspired by quantum molecular simulations, we introduce ECloudGen, a generative model that leverages electron clouds as meaningful latent variables. ECloudGen incorporates techniques such as latent diffusion models, Llama architectures and a contrastive learning task, which organizes the chemical space into a structured and highly interpretable latent representation. Benchmark studies demonstrate that ECloudGen outperforms state-of-the-art methods by generating more potent binders with superior physiochemical properties and by covering a broader chemical space. The incorporation of electron clouds as latent variables not only improves generative performance but also introduces model-level interpretability, as illustrated in our case studies.
- 15 October 2025
- Published by Springer Nature in Nature Computational Science
- Vol. 5 (11) , 1017-1028
ECloudGen: leveraging electron clouds as a latent variable to scale up structure-based molecular design
Structure-based molecule generation represents a notable advancement in artificial intelligence-driven drug design. However, progress in this field is constrained by the scarcity of structural data on protein–ligand complexes. Here we propose a latent variable approach that bridges the gap between ligand-only data and protein–ligand complexes, enabling target-aware generative models to explore a broader chemical space, thereby enhancing the quality of molecular generation. Inspired by quantum molecular simulations, we introduce ECloudGen, a generative model that leverages electron clouds as meaningful latent variables. ECloudGen incorporates techniques such as latent diffusion models, Llama architectures and a contrastive learning task, which organizes the chemical space into a structured and highly interpretable latent representation. Benchmark studies demonstrate that ECloudGen outperforms state-of-the-art methods by generating more potent binders with superior physiochemical properties and by covering a broader chemical space. The incorporation of electron clouds as latent variables not only improves generative performance but also introduces model-level interpretability, as illustrated in our case studies.